On December22, 2021, Exopharm Limited (ASX:EX1) announced that it has been granted US patent US 11202805 for its LEAP™ exosome purification technology. The company said that this patent positions Exopharm as a global leader in meeting the challenge of large-scale, commercial production of exosomes needed to enable leading-edge exosome medicines. The latest research points to exosomes as a possibly better and safer way to deliver modern medicines, including mRNA vaccines that currently use lipid nanoparticles.
Login Or Register To Read Full Story